PROTACing the androgen receptor and other emerging therapeutics in prostate cancer-Reference-Cited by-同舟云学术

PROTACing the androgen receptor and other emerging therapeutics in prostate cancer

Published:2024-07-22 Issue:9 Volume:24 Page:829-835
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Zang Peter D.¹,Seylani Allen²,Yu Evan Y.³⁴,Dorff Tanya B.¹

Affiliation:

1. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

2. University of California Riverside School of Medicine, Los Angeles, CA, USA

3. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

4. Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA

Funder

U.S. Department of Health and Human Services

Center for Cancer Research

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2379913

Reference49 articles.

1. Cancer statistics, 2023

2. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins C;Cancer Res,1941

3. High Androgen Receptor Levels Are Predictive of Decreased Survival in Prostate Cancer

4. Pathogenesis of prostate cancer and hormone refractory prostate cancer

5. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Analysis of Treatment Resistant Cancer Cells;2024-08-31